Unknown

Dataset Information

0

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.


ABSTRACT: Motor complications in Parkinson's disease (PD) are associated with long-term oral levodopa treatment and linked to pulsatile dopaminergic stimulation. L-dopa-carbidopa intestinal gel (LCIG) is delivered continuously by percutaneous endoscopic gastrojejunostomy tube (PEG-J), which reduces L-dopa-plasma-level fluctuations and can translate to reduced motor complications. We present final results of the largest international, prospective, 54-week, open-label LCIG study. PD patients with severe motor fluctuations (>3 h/day "off" time) despite optimized therapy received LCIG monotherapy. Additional PD medications were allowed >28 days post-LCIG initiation. Safety was the primary endpoint measured through adverse events (AEs), device complications, and number of completers. Secondary endpoints included diary-assessed off time, "on" time with/without troublesome dyskinesia, UPDRS, and health-related quality-of-life (HRQoL) outcomes. Of 354 enrolled patients, 324 (91.5%) received PEG-J and 272 (76.8%) completed the study. Most AEs were mild/moderate and transient; complication of device insertion (34.9%) was the most common. Twenty-seven (7.6%) patients withdrew because of AEs. Serious AEs occurred in 105 (32.4%), most commonly complication of device insertion (6.5%). Mean daily off time decreased by 4.4 h/65.6% (P?

SUBMITTER: Fernandez HH 

PROVIDER: S-EPMC4674978 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications


Motor complications in Parkinson's disease (PD) are associated with long-term oral levodopa treatment and linked to pulsatile dopaminergic stimulation. L-dopa-carbidopa intestinal gel (LCIG) is delivered continuously by percutaneous endoscopic gastrojejunostomy tube (PEG-J), which reduces L-dopa-plasma-level fluctuations and can translate to reduced motor complications. We present final results of the largest international, prospective, 54-week, open-label LCIG study. PD patients with severe mot  ...[more]

Similar Datasets

| S-EPMC3661282 | biostudies-literature
| S-EPMC10473130 | biostudies-literature
| S-EPMC7396832 | biostudies-literature
| S-EPMC5066747 | biostudies-literature
| S-EPMC7604637 | biostudies-literature
| S-EPMC8633325 | biostudies-literature
| S-EPMC9292774 | biostudies-literature
| S-EPMC5833238 | biostudies-literature
| S-EPMC4168384 | biostudies-literature
| S-EPMC5784118 | biostudies-literature